Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 13/20 | 0.52 |
| ▸ | NAMPT | P43490 | 3/20 | 0.39 |
| ▸ | BIRC2 | Q13490 | 1/20 | 0.39 |
| ▸ | CTSK | P43235 | 1/20 | 0.38 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13594509 | 1.00 | ELANE (0.52) | ELANENAMPTBIRC2CTSKKLK5 | |
| SCHEMBL4406568 | 0.92 | ELANE (0.54) | ELANENAMPTBIRC2CTSK | |
| SCHEMBL13594510 | 0.92 | ELANE (0.54) | ELANENAMPTBIRC2CTSK | |
| SCHEMBL8038460 | 0.91 | ELANE (0.46) | ELANEBIRC2 | |
| SCHEMBL12726041 | 0.90 | ELANE (0.46) | ELANENAMPTBIRC2 | |
| SCHEMBL15213290 | 0.89 | ELANE (0.43) | ELANEBIRC2 | |
| SCHEMBL16413340 | 0.89 | ELANE (0.43) | ELANEBIRC2 | |
| SCHEMBL8241586 | 0.86 | ELANE (0.40) | ELANENAMPTCTSKKLK5 | |
| SCHEMBL4407737 | 0.86 | ELANE (0.40) | ELANENAMPTCTSKKLK5 | |
| SCHEMBL13573805 | 0.85 | ELANE (0.40) | ELANENAMPTCTSKKLK5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090304631-A1 | HEPATITIS C SERINE PROTEASE INHIBITORS AND USES THEREFOR | PHENOMIX CORPORATION | 2009-12-10 | — | — | US | disclosed |
| EP-2029153-A2 | HEPATITIS C SERINE PROTEASE INHIBITORS AND USES THEREFOR | Phenomix Corporation (US) | 2009-03-04 | — | — | EP | disclosed |
| WO-2007089618-A2 | HEPATITIS C SERINE PROTEASE INHIBITORS AND USES THEREFOR | PHENOMIX CORPORATION (US) | 2007-08-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090304631-A1 | HEPATITIS C SERINE PROTEASE INHIBITORS AND USES THEREFOR | PREP, CTSC, PEPD | ELANE 208/4885NAMPT 487/4885BIRC2 383/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.